As reviewed in this paper, meningococcal disease epidemiology varies substantially by
geographic area and time. The disease can occur as sporadic cases, outbreaks, and large …

No broadly effective vaccines are available for prevention of group B meningococcal
disease, which accounts for> 50% of all cases. The group B capsule is an autoantigen and …

Background. In the absence of an efficacious broadly protective vaccine, serogroup B
Neisseria meningitidis (MenB) is the leading cause of bacterial meningitis and septicemia in …

Factor H binding proteins (fHBP), are bacterial surface proteins currently undergoing human
clinical trials as candidate serogroup B Neisseria meningitidis (MnB) vaccines. fHBP protein …

Advances in genomics and innovative strategies such as reverse vaccinology have changed
the concepts and approaches to vaccine candidate selection and design. Genome mining …

Abstract Background Recombinant forms of Neisseria meningitidis human factor H binding
protein (fHBP) are undergoing clinical trials in candidate vaccines against invasive …

Background: An investigational vaccine against serogroup B meningococcal (MenB)
disease containing 3 main recombinant proteins (factor H-binding protein, Neisserial …

Neisseria meningitidis is a Gram-negative microorganism that exists exclusively in humans
and can cause devastating invasive disease. Although capsular polysaccharide-based …

The sequence variability of protective antigens is a major challenge to the development of
vaccines. For Neisseria meningitidis, the bacterial pathogen that causes meningitis, the …

Serogroup B meningococcal (MenB) disease remains a serious public health problem for
which a cross-protective vaccine effective against a wide range of MenB isolates has not …